Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
This study is currently recruiting participants.
(see Contacts and Locations)
Verified September 2014 by Children's Research Institute
Sponsor:
D. Ashley Hill, M.D.
Information provided by (Responsible Party):
D. Ashley Hill, M.D., Children's Research Institute
ClinicalTrials.gov Identifier:
NCT00565903
First received: November 29, 2007
Last updated: September 9, 2014
Last verified: September 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined. We are working to identify the genetic factors which may contribute to the development of this rare tumor.
| Condition |
|---|
|
Pleuropulmonary Blastoma Cystic Nephroma Sertoli-Leydig Cell Tumor of Ovary Medulloepithelioma Embryonal Rhabdomyosarcoma of Cervix |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
| Official Title: | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
Resource links provided by NLM:
Genetics Home Reference related topics:
DICER1 syndrome
MedlinePlus related topics:
Cancer
Genetic and Rare Diseases Information Center resources:
Blastoma
Malignant Mesenchymal Tumor
Ovarian Cancer
Pleuropulmonary Blastoma
Rhabdomyosarcoma Embryonal
Sertoli-leydig Cell Tumors
Soft Tissue Sarcoma
Testicular Cancer
U.S. FDA Resources
Further study details as provided by Children's Research Institute:
Primary Outcome Measures:
- Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
We are collecting blood samples or saliva samples. When available, we also collect tumor samples from prior surgical procedures.
| Estimated Enrollment: | 2000 |
| Study Start Date: | March 2005 |
| Estimated Study Completion Date: | December 2020 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | up to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are invited to participate.
Criteria
Inclusion Criteria:
- child or adult diagnosed with pleuropulmonary blastoma or cystic nephroma.
Exclusion Criteria:
- child or adult who does not have a confirmed diagnosis of pleuropulmonary blastoma or cystic nephroma.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00565903
Please refer to this study by its ClinicalTrials.gov identifier: NCT00565903
Contacts
| Contact: Dana Ashley Hill, M.D. | 202-476-2051 | dashleyhill@gmail.com | |
| Contact: Leslie A. Doros, M.D. | 202-476-2051 | ldoros@childrensnational.org |
Locations
| United States, District of Columbia | |
| Children's National Medical Center | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: D Ashley Hill, MD 202-476-2051 dashill@childrensnational.org | |
| Contact: Leslie Doros, MD 202-476-2051 ldoros@childrensnational.org | |
| Principal Investigator: Ashley Hill, MD | |
| Sub-Investigator: Leslie Doros, MD | |
Sponsors and Collaborators
D. Ashley Hill, M.D.
Investigators
| Study Chair: | D. Ashley Hill, MD | Children's Research Institute | |
| Study Director: | Yoav Messinger, MD | Children's Hospital and Clinics of Minnesota |
More Information
Additional Information:
No publications provided
| Responsible Party: | D. Ashley Hill, M.D., MD, Division Chief Pathology, Children's Research Institute |
| ClinicalTrials.gov Identifier: | NCT00565903 History of Changes |
| Other Study ID Numbers: | 05-0192 / 201012830 |
| Study First Received: | November 29, 2007 |
| Last Updated: | September 9, 2014 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Children's Research Institute:
|
pleuropulmonary blastoma PPB cystic nephroma |
Additional relevant MeSH terms:
|
Leydig Cell Tumor Pulmonary Blastoma Rhabdomyosarcoma, Embryonal Sertoli-Leydig Cell Tumor Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Genital Diseases, Female Genital Diseases, Male Genital Neoplasms, Female Genital Neoplasms, Male Gonadal Disorders Lung Neoplasms Myosarcoma Neoplasms |
Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplasms, Connective and Soft Tissue Neoplasms, Gonadal Tissue Neoplasms, Muscle Tissue Ovarian Diseases Ovarian Neoplasms Respiratory Tract Neoplasms Rhabdomyosarcoma Sarcoma Sex Cord-Gonadal Stromal Tumors Testicular Diseases Testicular Neoplasms Thoracic Neoplasms |
ClinicalTrials.gov processed this record on March 03, 2015